PEG 6000

The aim of the study was to improve the solubility of aceclofenac, which is poorly water soluble drug belongs to BCS class-II. Aceclofenac appears to be particularly well tolerated among the NSAIDs, with a lower incidence of gastrointestinal adverse effects. For poorly soluble orally administered drugs, the rate of absorption is often controlled by the rate of dissolution. To improve the solubility of drug by solid dispersions were prepared with different methods like physical mixture, kneading method and solvent evaporation method with various carriers like poloxamer188, poloxamer407 and PEG 6000 in different ratios from 1:1 to 1:5. The prepared formulations were evaluated for physicochemical characteristics, characterized by differential scanning calorimetry (DSC), X-ray diffraction (XRD), in-vitro dissolution studies and saturation solubility. Based on the evaluation parameters poloxamer407 in ratio of 1:5 through solvent evaporation method was optimized and formulated into tablets by direct compression method. These tablets showed a higher in-vitro dissolution drug release which is 99.62% in 30 minutes when compared with pure drug which showed 26.62% in 60 minutes, whereas marketed tablet (Hifenac) shows 99.64±0.10% in 40 minutes. Hence it was concluded that solid dispersion of aceclofenac drug by using polaxamer 407 with solvent evaporation method enhances solubility, absorption rate and increase bioavailability of the aceclofenac drug.

The aim of this study was increasing the bioavailability of poorly water soluble, atorvastatin calcium (ATC) via preparation of solid dispersion then incorporating it in floating tablets for oral use. Physical mixtures of ATC were prepared by mixing the appropriate amounts of ATC and carriers (PVP k-2000, PEG 6000 and skimmed milk) in geometric proportions using a mortar and pestle, until a homogeneous mixture was obtained. Solid dispersions of ATC with all carriers   were prepared at ratios of (1:1, 1:3, 1:5, 1:7 and 1:9 drug to carrier ratio w/w) by three methods, kneading method, solvent evaporation and melting method. Evaluation of solid dispersion was done by studying the phase solubility, in-vitro dissolution, FTIR spectroscopy, DSC and X-ray powder diffractometry. The selected solid dispersion formulation was incorporated in floating tablets which were prepared by melting granulation method. Evaluation of floating tablets was done by determination of tablet thickness, diameter, weight uniformity, content uniformity, hardness, friability, in-vitro dissolution, in-vitro buoyancy in addition to bioavailability studies. PEG 6000, PVP k-2000 and skimmed milk increased the solubility of ATC by 180, 290 and 1200 folds, respectively. Solid dispersion prepared using PEG 6000 (S2, 1:3 drug: polymer ratio) gave the highest % drug released than PVP k-2000 and skimmed milk. Floating tablet formulation (T1) showed the best drug dissolution rate which is 102.18% after 24 h. Bioavailability results showed that floating tablets containing ATC solid dispersion is effectively used for treatment of hyperlipedmia. Floating tablets contained PEG 6000 solid dispersion reduced the % of TC, TGS and LDL by 58.46, 32.00 and 91.21 %, respectively while the percent of HDL was raised by 11.11%.

The aim of the present study is to enhance solubility of simvastatin by solid dispersion technique. Solid dispersions were prepared by fusion method by using various polymers. Formulation is optimized on the basis of acceptable solid dispersion properties and in-vitro release. In order to obtained best optimized product, 5 different formulations were developed. Different polymers like PEG 6000, HPMC 6000,HPC 1000 were taken as variables. Angle of repose, carr’s index, particle size, drug content and dissolution study were studied as response variables. The different physical properties showed best comparable results with drug. But higher percentage of drug release was observed when the formulation contained PEG6000 in 1:1.5 ratio (f5) compared to other formulations. Form this study it concluded that formulation (f5) which contained PEG (1:1.5) as polymer showed best dissolution profile compared to the drug. The formulation contained PEG 6000 was selected as optimized product.

Oral fast disintegrating films (OFDF) is an emerging technology brings out “formulations taken without water” with quick onset of action and improved patient compliance. The present aim of study is to enhance the dissolution rate of the dosage form by using the different superdisintegrants and co-processed superdisintegrants. The films were prepared by solvent casting method using hydrophilic polymers that rapidly dissolves on the tongue or buccal cavity, delivering the drug to the systemic circulation. The polymer was used  HPMC E15, PEG 6000 as plasticizer, citric acid as the saliva stimulating agent, sucrose as the sweetening agents and sodium starch glycolate, crosscarmelose sodium and crospovidone as the superdisintegrants and tween 80 as surfactant . The FTIR reports suggest that drug and excipients were compatible. These oral disintegrating films were evaluated for various evaluation parameters. The in-vitro dissolution studies were conducted as per USP II with sinker. There were three ODFs prepared by using different types of the superdisintegrants, two were prepared by using the co-processed superdisintegrants and one was without any superdisintegrants. Among all formulation, the F6 shown the better in-vitro drug release profile which was prepared by using co-procesed superdisintegrants. It can be concluded that the co-processed superdisintegrants enhances the dissolution rate by comparing with other formulation.